The verdict
Our read at a glance.
Whether p28's tumor-cell-penetrating, p53-stabilizing mechanism produces real clinical benefit in cancer, separate from broad claims about the peptide.
- The signal
- Early-phase trials of p28 in adults with advanced solid tumors and in children with recurrent central nervous system tumors reported that it was generally well tolerated, with some signals of activity. The evidence is early-phase and there is no approval for any use.
- The unknown
- Whether the early signals translate into meaningful benefit in larger controlled trials, and in which cancers, which has not been established.
- Our read
- An early-phase cancer peptide, not a proven or approved therapy. p28's tumor-targeting mechanism and early tolerability are notable, but it remains investigational oncology research and should be read that way.
The mechanism
How it works.
p28 is a 28-amino-acid fragment of azurin, a protein from the bacterium Pseudomonas aeruginosa, and it acts as a cell-penetrating peptide that preferentially enters cancer cells. Once inside, it binds the tumor-suppressor protein p53 and blocks COP1 from tagging it for destruction, so p53 builds up and can switch cancer cells back toward growth arrest. This mechanism is supported by cell and animal work plus early-phase human trials, but it has not been shown to produce meaningful benefit in larger controlled cancer studies.
Safety & regulatory boundary
The consequential part.
p28 is investigational and not an approved product. Its evidence is early-phase and specific to cancer settings under medical supervision. Results in early trials do not establish benefit, and research-labeled or compounded p28 is not an approved product. Its mechanism does not validate any wellness, longevity, or general health claims.
What's next
What we're watching.
Later-phase oncology trials, the specific cancers where it may help, and longer-term safety data.
Context
Why this is discussed.
p28 is an unusual cancer drug candidate because it is a peptide that selectively enters tumor cells, and its early trials in adults and children drew attention as a gentler targeted approach.
The evidence base
14 cited references.
Registered trials2
ClinicalTrials.gov · PHASE1 · COMPLETED · 2013-08
ClinicalTrials.gov · PHASE1 · COMPLETED · 2009-04
Indexed literature (PubMed)12
Huang F et al. · Protein J · 2020
Yaghoubi A et al. · Front Oncol · 2020
Joy A et al. · Phys Chem Chem Phys · 2026
Jia L et al. · Cancer Chemother Pharmacol · 2011
Cantini F et al. · J Pept Sci · 2021
Sasidharan S et al. · Mol Divers · 2021
Santini S et al. · J Mol Recognit · 2011
Lulla RR et al. · Neuro Oncol · 2016
Bizzarri AR et al. · Biochim Biophys Acta Gen Subj · 2019
Yamada T et al. · Br J Cancer · 2013
Gorman GS et al. · J Pharm Biomed Anal · 2010
Raber HF et al. · Biomacromolecules · 2020
Keep reading